HLB Fails to Receive US FDA Approval for Rivoceranib Liver Cancer Treatment
HLB has failed to secure approval from the U.S. Food and Drug Administration (FDA) for its “Rivoceranib + Camrelizumab,” which is under development as a first-line treatment for liver cancer. On May 17, Chairman Jin Yang-gon of HLB announced via YouTube …